# Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections

> **NCT05258851** · PHASE3 · TERMINATED · sponsor: **King Faisal Specialist Hospital & Research Center** · enrollment: 29 (actual)

## Conditions studied

- Carbapenem-Resistant Enterobacteriaceae Infection

## Interventions

- **DRUG:** Ceftazidime-avibactam
- **DRUG:** Colistin

## Key facts

- **NCT ID:** NCT05258851
- **Lead sponsor:** King Faisal Specialist Hospital & Research Center
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2022-06-01
- **Primary completion:** 2023-04-12
- **Final completion:** 2024-01-28
- **Target enrollment:** 29 (ACTUAL)
- **Why stopped:** Difficulties encountered in the recruitment process and slow enrollment. The study was not terminated due to any safety issues or concerns.
- **Last updated:** 2024-06-14


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05258851

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05258851, "Ceftazidime-Avibactam Use in Critically Ill Patients With Carbapenem-Resistant Enterobacteriaceae Infections". Retrieved via AI Analytics 2026-09-04 from https://api.ai-analytics.org/clinical/NCT05258851. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*